Our findings also suggest a remaining large addressable market for obesity treatment, with 0.5% of patients without diabetes receiving GLP-1 RAs and 0.01% receiving surgery. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.